RIPK1 and amyotrophic lateral sclerosis: Similar to DAM, the increased number of RRIM and the corresponding upregulated proinflammatory genes in mice with ALS are also decreased via genetic or pharmacological inhibition of RIPK1 kinase activity, suggesting RIPK1 kinase activity is a potential therapeutic target to ameliorate both DAM and RRIM-mediated neurotoxicity.